-
2 weeks ago | 
pharmacytimes.com | Gillian McGovern
In the phase 3 neoCARHP clinical trial (NCT04858529), taxane, trastuzumab, and pertuzumab (THP) provided noninferior pathological complete response rates (pCRs) and improved tolerability in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer compared with taxane, carboplatin, and trastuzumab plus pertuzumab (TCbHP).
-
2 weeks ago | 
pharmacytimes.com | Gillian McGovern
Compared with fulvestrant (Faslodex; AstraZeneca), vepdegestrant (ARV-471; Arvinas, Pfizer) demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) in pretreated patients with ESR1-mutated estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer.
-
3 weeks ago | 
pharmacytimes.com | Gillian McGovern
Study findings published in Advanced Science show that a novel regulatory axis appears to be linked to dysregulated lipid metabolism with hepatocellular carcinoma (HCC) progression, highlighting potential epigenetic and metabolic targets for therapeutic intervention.
-
3 weeks ago | 
pharmacytimes.com | Gillian McGovern
Camizestrant (AstraZeneca), used in combination with a CDK4/6 inhibitor, resulted in a statistically significant and clinically meaningful improvement in progression-free survival (PFS) when used as a first-line treatment in patients with ESR1-mutated hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer.
-
3 weeks ago | 
pharmacytimes.com | Gillian McGovern
Prespecified analyses published in the Journal of the American Society of Nephrology demonstrated that the safety and efficacy of vadadustat (Vafseo; Akebia Therapeutics) and darbepoetin alfa (Aranesp; Amgen) in patients with dialysis-dependent chronic kidney disease (DD-CKD) both inside and outside the US were similar.
-
3 weeks ago | 
pharmacytimes.com | Gillian McGovern
The CDC advises that US residents who are traveling internationally should receive a measles, mumps, and rubella vaccination (MMR), regardless of the country they are visiting.
-
3 weeks ago | 
pharmacytimes.com | Gillian McGovern
Metabolic dysfunction–associated steatohepatitis (MASH)–related cirrhosis is increasingly prevalent among patients with metabolic dysfunction–associated steatotic liver disease (MASLD) and is associated with substantial morbidity and mortality because of hepatic decompensation, hepatocellular carcinoma, major adverse cardiovascular events, and all-cause mortality, wrote authors of a review published in Journal of Translational Gastroenterology.
-
3 weeks ago | 
pharmacytimes.com | Gillian McGovern
Study findings demonstrated that the addition of carboplatin (Paraplatin; Bristol-Myers Squibb) to paclitaxel (Taxol; Pfizer) following dose-dense doxorubicin (Adriamycin; Pfizer)/cyclophosphamide (Cytoxan; Baxter Healthcare) for adjuvant therapy of node-positive or high-risk node-negative triple-negative breast cancer (TNBC) did not result in statistically significant improvements in invasive disease-free survival (IDFS), distant recurrence/relapse-free interval (DRFI), or overall survival...
-
3 weeks ago | 
pharmacytimes.com | Gillian McGovern
The pivotal phase 3 PIVOT-PO clinical trial (NCT06059846) evaluating tebipenem pivoxil hydrobromide (Tebipenem HBr; Spero Therapeutics and GSK), an investigational treatment for complicated urinary tract infections (cUTIs), met its primary end point and stopped early for efficacy, according to a news release.
-
3 weeks ago | 
pharmacytimes.com | Gillian McGovern |David R. Spigel
Pharmacy Times® interviewed David Spigel, MD, medical oncologist,chief scientific officer at Sarah Cannon Research Institute, who discussed a study on patients with early-stage non-small cell lung cancer (NSCLC) to determine the need for chemotherapy, of which the findings were presented as part of the 2025 American Society of Clinical Oncology Annual Meeting.
